Comparative Pharmacology
Head-to-head clinical analysis: DIPRIVAN versus KETALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPRIVAN versus KETALAR.
DIPRIVAN vs KETALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.
None Documented
None Documented
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Terminal elimination half-life: 2.5-3 hours (ketamine); norketamine: 12 hours. Clinical context: Short half-life facilitates rapid recovery, but context-sensitive half-life increases with infusion duration.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Renal: 90% as metabolites (norketamine, dehydronorketamine); unchanged: 2-4%. Fecal: <3%.
Category C
Category C
General Anesthetic
General Anesthetic